Oxford University Coronavirus Vaccine Trial Produces Strong Immune Response

An early human trial of Oxford University’s experimental coronavirus vaccine has yielded a strong immune response in hundreds of people, according to newly released data.

The potential vaccine, which the U.K. university developed in partnership with drugmaker AstraZeneca, was administered in a trial that involved 1,077 people and caused an immune response in people aged 18 to 55 that lasted two months or slightly longer, according to data published Monday by the medical journal The Lancet. The vaccine, which is made from a combination of coronavirus genetic material and a virus that causes the common cold in chimpanzees, caused the body to produce antibodies against the coronavirus and caused a reaction in T-cells, a type of white blood cell that also helps stave off infection.